{"id":"gonapeptyl","safety":{"commonSideEffects":[{"rate":"60-80","effect":"Hot flashes"},{"rate":"40-60","effect":"Decreased libido"},{"rate":"30-50","effect":"Erectile dysfunction"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"10-15","effect":"Headache"},{"rate":null,"effect":"Bone density loss (with prolonged use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a GnRH agonist, Gonapeptyl binds to GnRH receptors in the pituitary gland, initially causing a surge in LH and FSH release (flare effect), followed by sustained suppression of these hormones through receptor desensitization. This results in profound suppression of testosterone in males and estrogen in females, making it useful for hormone-dependent conditions.","oneSentence":"Gonapeptyl is a GnRH (gonadotropin-releasing hormone) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:33:05.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer (hormone-sensitive)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT06175832","phase":"PHASE4","title":"PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-01-27","conditions":"Ovarian Stimulation, Quality of Life, Preimplantation Genetic Testing","enrollment":60},{"nctId":"NCT04157725","phase":"PHASE4","title":"Mild Stimulation Protocol Using Clomiphene Citrate for Women With PCOS Undergoing in Vitro Fertilization","status":"UNKNOWN","sponsor":"American University of Beirut Medical Center","startDate":"2023-06-01","conditions":"PCO - Polycystic Ovaries, Infertility","enrollment":154},{"nctId":"NCT03115307","phase":"PHASE4","title":"Luteal Phase Support in Insemination Cycles","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2017-01","conditions":"Infertility, Female","enrollment":167},{"nctId":"NCT01468441","phase":"NA","title":"Ovarian Stimulation Using Recombinant Follicle-stimulating Hormone (FSH) and Gonadotrophin Releasing Hormone (GnRH) Agonist in Alternate Days","status":"COMPLETED","sponsor":"Fertility - Assisted Fertilization Center","startDate":"2011-09","conditions":"Infertility","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Gonapeptyl®","genericName":"Gonapeptyl®","companyName":"University Hospital, Ghent","companyId":"university-hospital-ghent","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gonapeptyl is a GnRH (gonadotropin-releasing hormone) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. Used for Prostate cancer (hormone-sensitive), Endometriosis, Uterine fibroids.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}